Overview

Efficacy of Nebulized Lidocaine, Salbutamol, and Beclomethasone Plus Salbutamol in the Covid-19 Patients With ARDS on Non-invasive Ventilation; Randomized Control Trial

Status:
Recruiting

Trial end date:
2021-08-01

Target enrollment:
0

Participant gender:
All

Summary

The COVID-19, a pandemic as declare by WHO1, has a devastating impact on health and economic worldwide2. Literature suggests that acute respiratory distress syndrome (ARDS) develops over 20% of the infected individuals with Coivd-pneumonia3 along with other symptoms like fever followed by cough and dyspnea as well as chest pain in severe cases4. The current preventative strategies are non-specific10, and current interventions are predominantly supportive1. Recently, some studies have demonstrated anti-inflammatory actions for local anesthetics including lidocaine.

Phase:

Phase 1

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Sheikh Zayed Medical College

Treatments:

Lidocaine

Criteria

Inclusion Criteria:

- Covid-19 positive

- Moderate to severe ARDS

Exclusion Criteria:

- patients with COPD or taking bronchodilators and steroids for chronic respiratory
illnesses